Tumor cells frequently down‑regulate surface MHC‑I to evade immune surveillance. Therapeutic approaches that up‑regulate MHC‑I hold promise for restoring effective CD8⁺ T‑cell monitoring and enhancing checkpoint‑blockade therapy efficacy. Inhibition of PIKfyve—a kinase that converts PI3P to PI(3,5)P...
ORGANISM(S): Homo sapiens
